Skip to content

Botulinum toxin type A

Botulinum toxin type A is a toxin type, or serotype, used in several distinct medicines. It reduces release of acetylcholine, a nerve-signaling chemical, by cleaving the release protein SNAP-25. Products in this category have therapeutic and aesthetic uses, but each has its own formulation, potency units, and regional approvals. Type A identifies shared biology; it does not identify a single medicine (Botox prescribing information, sections 1, 5.2, and 12.1 — DailyMed 🔗).

The following products illustrate the type A category; they are not an exhaustive worldwide list. Ingredient names retain U.S. suffixes where applicable. Those suffixes are part of the product name, not additional serotypes.

ProductActive ingredientCompany roles and product reference
Botox / Botox CosmeticOnabotulinumtoxinAAllergan, part of AbbVie; therapeutic and cosmetic uses have separate U.S. labels (Botox — DailyMed 🔗).
DysportAbobotulinumtoxinAIpsen Biopharm manufactures it; Galderma commercializes aesthetic Dysport in licensed territories (Dysport — DailyMed 🔗; Galderma brands 🔗).
XeominIncobotulinumtoxinAMerz Pharmaceuticals GmbH is the manufacturer named in U.S. product information (Xeomin — DailyMed 🔗).
JeuveauPrabotulinumtoxinA-xvfsDaewoong Pharmaceutical manufactures the product; Evolus commercializes Jeuveau in the U.S. (Jeuveau — DailyMed 🔗).
DaxxifyDaxibotulinumtoxinA-lanmRevance is named in the U.S. manufacturing statement; its label includes adult glabellar lines and cervical dystonia (Daxxify — DailyMed 🔗).
LetyboLetibotulinumtoxinA-wlbgHugel manufactures it; its U.S. label concerns adult glabellar lines (Letybo — DailyMed 🔗).
RelfydessRelabotulinumtoxinAGalderma developed and manufactures this ready-to-use liquid product; approvals remain regional (Galderma China approval announcement 🔗).

Relfydess is not FDA approved. In its October 22, 2026 update, Galderma targeted resubmission of the U.S. Biologics License Application (BLA) in the first quarter of 2027, subject to further regulatory feedback. This is a filing target, not a completed or accepted resubmission or an FDA approval date (Galderma third-quarter 2026 update 🔗; U.S. regulatory status).

Those products can share a serotype while remaining distinct regulated medicines. Shared type A biology does not create a universal conversion ratio, a common approval profile, or a general ranking.

Galderma announced Chinese approval of Relfydess for adult glabellar lines on October 23, 2026, with commercial launch expected in the second half of 2027. Chinese approval, a planned Chinese launch, and the U.S. filing target are separate milestones (Galderma China approval announcement 🔗).

Type A acts inside nerve endings that release acetylcholine, also called cholinergic nerve endings. Its light chain is an enzyme that cleaves SNAP-25, part of the SNARE protein machinery that helps chemical-signal packets fuse with the nerve-cell membrane. This interrupts acetylcholine release and can temporarily reduce activity in the affected muscles or glands (Botox mechanism of action, section 12.1 — DailyMed 🔗).

The broader sequence is covered in botulinum toxin mechanism of action. For comparison with type B, see botulinum toxin type A vs type B.

Type A products have a broad clinical and aesthetic footprint, but that footprint is not a single shared approval profile. A product may have strong evidence for one use, a different label in another region, and common discussion elsewhere that does not equal approval.

This distinction is especially important in comparison content. “Type A” can identify a mechanism family, but it does not answer which indications are approved, which warnings apply, how units are defined, or whether a product is available in a particular market.

For example, the U.S. Botox label includes chronic migraine, spasticity, bladder conditions, and other specified therapeutic uses. Daxxify’s U.S. label includes adult cervical dystonia as well as glabellar lines; Letybo’s label concerns adult glabellar lines. None of those labels creates a class-wide approval for every type A product (Botox — DailyMed 🔗; Daxxify — DailyMed 🔗; Letybo — DailyMed 🔗).

The U.S. FDA indication matrix compares current label scopes. U.S. regulatory status separately tracks applications, CRLs, and company filing plans.

Type A products use product-specific potency units. These measure biological activity using the product’s own assay rather than a universal mass-based scale. Botox Cosmetic product information explicitly states that its units cannot be compared with or converted into those of other botulinum toxin products. A larger headline unit number therefore does not establish greater strength, wider spread, longer duration, or greater safety (Botox Cosmetic potency-unit warning, section 5.1 — DailyMed 🔗).

This issue shapes how readers should approach diffusion claims, immunogenicity discussion, and brand comparisons. Type A is a useful category, but product-specific evidence carries the interpretive weight.

The U.S. Botox, Daxxify, and Letybo labels carry boxed warnings about toxin effects spreading beyond the injection site, including swallowing or breathing difficulties. A shared mechanism does not establish identical safety outcomes across products, doses, patient groups, or uses (Botox — DailyMed 🔗; Daxxify — DailyMed 🔗; Letybo — DailyMed 🔗).

Presentation is a separate distinction: Relfydess is supplied as a liquid requiring no reconstitution, while products such as Botox are supplied as powders requiring reconstitution. This changes preparation requirements; it does not establish comparative efficacy or safety (Relfydess data sheet — Medsafe 🔗; Botox — DailyMed 🔗).

1. Two medicines both contain botulinum toxin type A. What does that establish?
2. One type A product lists a larger unit number than another. What can be concluded from those numbers alone?
3. A type A product is approved for adult frown lines in one country. How does that affect other products and markets?